Isoniazid/piperine/rifampicin - Cadila Pharmaceuticals

Drug Profile

Isoniazid/piperine/rifampicin - Cadila Pharmaceuticals

Alternative Names: Risorine

Latest Information Update: 07 Feb 2014

Price : $50

At a glance

  • Originator Cadila Pharmaceuticals
  • Class Anti-inflammatories; Antibacterials; Antihyperlipidaemics; Antituberculars; Carboxylic acids; Hydrazines; Isonicotinic acids; Rifamycins
  • Mechanism of Action Cell wall inhibitors; DNA-directed RNA polymerase inhibitors; Sterol O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Tuberculosis

Most Recent Events

  • 11 Sep 2012 Cadila completes a phase IV trial in tuberculosis in India (CTRI/2012/11/003097)
  • 10 Sep 2012 Cadila completes a phase IV trial in tuberculosis in India (CTRI/2012/11/003096)
  • 10 Aug 2012 Cadila completes a phase IV trial in tuberculosis in India (CTRI/2012/06/002742)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top